Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program
L. Richeldi (Rome, Italy), V. Cottin (Lyon, France), L. Islam (Welwyn Garden City, United Kingdom), G. Jenkins (Nottingham, United Kingdom), N. Kamath (Welwyn Garden City, United Kingdom), Y. Inoue (Osaka, Japan), N. Parmar (Welwyn Garden City, United Kingdom), J. Randhawa (Welwyn Garden City, United Kingdom), G. Raghu (Washington, United States of America)
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Richeldi (Rome, Italy), V. Cottin (Lyon, France), L. Islam (Welwyn Garden City, United Kingdom), G. Jenkins (Nottingham, United Kingdom), N. Kamath (Welwyn Garden City, United Kingdom), Y. Inoue (Osaka, Japan), N. Parmar (Welwyn Garden City, United Kingdom), J. Randhawa (Welwyn Garden City, United Kingdom), G. Raghu (Washington, United States of America). Challenges in setting up Phase III idiopathic pulmonary fibrosis studies during the COVID-19 pandemic: Experience from the STARSCAPE program. 462
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: